Statements (70)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquired |
Celularity, Inc.
|
| gptkbp:addressed |
unmet medical needs
|
| gptkbp:advocates_for |
regenerative medicine advancements
|
| gptkbp:aims_to |
gptkb:healthcare_organization
autoimmune diseases regulatory approvals degenerative diseases |
| gptkbp:ceo |
gptkb:Robert_Hariri
|
| gptkbp:clinical_trial |
multiple ongoing clinical trials
|
| gptkbp:collaborated_with |
academic institutions
clinical studies biotech firms |
| gptkbp:collaborations |
research partners
|
| gptkbp:constructed_in |
strategic alliances
|
| gptkbp:created |
innovative products
|
| gptkbp:data_usage |
clinical trials
|
| gptkbp:developer |
therapeutic solutions
|
| gptkbp:develops |
allogeneic cell therapies
|
| gptkbp:employs |
gptkb:physicist
clinical staff |
| gptkbp:engages_in |
healthcare providers
|
| gptkbp:explores |
new treatment modalities
|
| gptkbp:focuses_on |
gptkb:drug
quality assurance sustainable practices patient-centric solutions |
| gptkbp:fosters |
innovation in biotechnology
|
| gptkbp:founded |
gptkb:2016
|
| gptkbp:has_product |
various therapeutic candidates
|
| gptkbp:headquarters |
gptkb:Cranbury,_New_Jersey
|
| https://www.w3.org/2000/01/rdf-schema#label |
Celularity Therapeutics
|
| gptkbp:influenced_by |
next-generation therapies
|
| gptkbp:investment |
research and development.
|
| gptkbp:is_engaged_in |
patient advocacy
clinical research |
| gptkbp:is_enhanced_by |
patient outcomes
|
| gptkbp:is_implemented_in |
best practices
|
| gptkbp:is_involved_in |
regenerative medicine
|
| gptkbp:is_known_for |
innovative therapies
|
| gptkbp:is_part_of |
biotech ecosystem
|
| gptkbp:is_recognized_for |
scientific advancements
|
| gptkbp:is_supported_by |
gptkb:Company
|
| gptkbp:led_to |
experienced executives
|
| gptkbp:notable_recipients |
gptkb:Research_Institute
|
| gptkbp:origin |
cell-based therapies
|
| gptkbp:participated_in |
conferences
|
| gptkbp:partnership |
various research institutions
|
| gptkbp:partnerships |
clinical trials
pharmaceutical companies |
| gptkbp:products |
chronic diseases
|
| gptkbp:promotes |
awareness of cell therapies
|
| gptkbp:receives_funding_from |
venture capital firms
|
| gptkbp:relationship |
stakeholders
|
| gptkbp:research |
immune system modulation
cell therapies |
| gptkbp:research_and_development |
market access
novel therapies |
| gptkbp:research_focus |
tissue regeneration
cellular immunotherapy immune modulation |
| gptkbp:research_interest |
clinical development
|
| gptkbp:stock_exchange |
gptkb:theorem
|
| gptkbp:symbol |
CELU
|
| gptkbp:technology |
cell manufacturing
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:uses |
placental-derived cells
|
| gptkbp:utilizes |
gptkb:smartphone
|
| gptkbp:bfsParent |
gptkb:Celularity_Inc.
|
| gptkbp:bfsLayer |
6
|